Aquestive Therapeutics (AQST) Total Debt (2017 - 2026)

Aquestive Therapeutics' Total Debt history runs 10 years deep, the most recent figure standing at $38.8 million for Q1 2026.

• In Q1 2026, Total Debt rose 14.77% year-over-year to $38.8 million; the TTM figure through Mar 2026 stood at $38.8 million (up 14.77% YoY), while the FY2025 annual figure was $37.5 million, up 15.33% from the prior year.
• Total Debt was $38.8 million for Q1 2026 at Aquestive Therapeutics, up from $37.5 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $54.2 million in Q1 2022 to a low of $17.5 million in Q2 2024.
• Historically, Total Debt has averaged $37.7 million across 5 years, with a median of $37.5 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Total Debt plunged 55.31% in 2024, then soared 100.1% in 2025.
• A 5-year view of Total Debt shows it stood at $52.1 million in 2022, then sank by 47.21% to $27.5 million in 2023, then rose by 18.15% to $32.5 million in 2024, then advanced by 15.33% to $37.5 million in 2025, then increased by 3.32% to $38.8 million in 2026.
• The last three Total Debt figures came in at $38.8 million (Q1 2026), $37.5 million (Q4 2025), and $36.3 million (Q3 2025), per Business Quant data.